Neoprobe, under license from the University of California San Diego Cancer Center, is developing 99mTc-DTPA-mannosyl-dextran (Lymphoseek) as a potential agent for imaging lymph nodes in patients undergoing treatment for breast cancer and melanoma. Phase II trials of Lymphoseek were initiated in mid 2006.